Combating Alzheimer’s Disease: Design and Synthesis of a Novel Drug Molecule for Targeted Metal Chelation Therapy
JSHS · 2025
Overview
Purpose: Alzheimer’s Disease (AD) is the sixth leading cause of death, and there is an urgent need for innovative treatments. Metal dyshomeostasis, a hallmark for AD, is characterized by the accumulation of certain toxic metal-ions in the brain. These metals catalyze the production of free radicals, resulting in metal -induced oxidative stress and exacerbating neurodegeneration. Metal chelators selectively bind to metal-ions to form stable complexes that can be safely excreted from the body, thereby alleviat ing oxidative stress in AD. Therefore, this study aims to synthesize a novel metal chelator as a potential therapeutic agent for targeting. Methods: A ligand was synthesized, and its structure was confirmed utilizing Nuclear Magnetic Resonance spectroscopy. UV-Visible spectroscopy was implemented to assess the metal-chelating ability. Finally, the logP test was performed to determine the molecule’s ability to penetrate the Blood-Brain Barrier. It was hypothesized that the ligand would effectively chelate t oxic metals, specifically targeting Fe(III), Zn(II), and Cu(II), thereby mitigating metal -induced oxidative stress as a potential treatment for AD. Results: The results revealed that the novel ligand exhibits metal -chelating properties and has therapeutic potential for combatting AD progression. A one-way ANOVA was conducted and revealed that the data is statistically significant. The research hypothesis was supported. Conclusion: The efficacy of the novel molecule stems from its structural properties, chemical behavior, and drug-likeness. Chemically, Schiff bases form strong coordinate covalent bonds with specific metal centers, possess enhanced binding affinities, and electron delocalization, making them ideal candidates for targeted metal-chelation therapies aimed at mitigating AD.
Competition history
- JSHS 2025
Resources
Related projects
ISEF · 2024
Synthesizing a Novel Family of Multifactorial Inhibitors to Treat Alzheimer's
ISEF · 2014
Novel Analysis of Oxidative Stress and Inflammation on Amyloid-beta, Tau, and Motility in Transgenic C. elegans models: Targeting Potential Therapeutics for Alzheimer’s Disease
ISEF · 2014
Development of a Therapeutic Drug for Alzheimer’s Disease: A Chemical Approach to Cease Amyloidosis
ISEF · 2018
Attacking Alzheimer's: Developing New Drugs Using Computational Modeling of Beta-Amyloid Protein Binding
ISEF · 2024
Using Novel Benzimidazole Sulfonate Derivatives for Inhibitory Activity on Enzymes Associated with Alzheimer's Disease
ISEF · 2026
A Multi-Target Chronopharmacotherapy for the Inhibition and Clearance of Toxic Proteins in Alzheimer's Disease
ISEF · 2022
Computational and Experimental Design of a Novel Acetylcholinesterase Inhibitor: Silanediols for Alzheimer's Disease Treatment
ISEF · 2026
Discovering a Path from Molecular Modeling to Alzheimer's Phytotherapeutics: Characterizing Novel GSK3ß Inhibitors in silico and in vitro
Closest projects by meaning, across every fair and year in the corpus.